Hernàndez-Èvole H, Briz-Redón Á, Berenguer M. Changing delta hepatitis patient profile: A single center experience in Valencia region, Spain. World J Hepatol 2020; 12(6): 277-287 [PMID: 32742570 DOI: 10.4254/wjh.v12.i6.277]
Corresponding Author of This Article
Marina Berenguer, MD, Professor, Liver Transplantation and Hepatology Unit, Hospital Universitari I Politècnic La Fe, Avenue Abril Martorell, 106, Valencia 46026, Spain. marina.berenguer@uv.es
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Case Control Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Jun 27, 2020; 12(6): 277-287 Published online Jun 27, 2020. doi: 10.4254/wjh.v12.i6.277
Changing delta hepatitis patient profile: A single center experience in Valencia region, Spain
Helena Hernàndez-Èvole, Álvaro Briz-Redón, Marina Berenguer
Helena Hernàndez-Èvole, Marina Berenguer, Departament de Medicina, University of València, Valencia 46010, Spain
Álvaro Briz-Redón, Statistics Office, City Council of València, Valencia 46002, Spain
Marina Berenguer, Liver Transplantation and Hepatology Unit, Hospital Universitari I Politècnic La Fe, Valencia 46026, Spain
Marina Berenguer, CIBERehd, Instituto de Salud Carlos III, Madrid 28029, Spain
Marina Berenguer, ISS La Fe, Valencia 46026, Spain
Author contributions: Hernàndez-Èvole H performed the research and wrote the manuscript; Berenguer M designed the study and corrected the manuscript; Briz-Redón A was involved in the statistical analysis.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board.
Conflict-of-interest statement: Marina Berenguer has received a grant from Gilead, has been advisor for Abbvie and Intercept, and has been a speaker and/or moderator in meetings organized by Abbvie, Gilead, Intercept, Novartis and Astellas. All authors have nothing to disclose.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Marina Berenguer, MD, Professor, Liver Transplantation and Hepatology Unit, Hospital Universitari I Politècnic La Fe, Avenue Abril Martorell, 106, Valencia 46026, Spain. marina.berenguer@uv.es
Received: February 9, 2020 Peer-review started: February 9, 2020 First decision: March 18, 2020 Revised: April 7, 2020 Accepted: May 5, 2020 Article in press: May 5, 2020 Published online: June 27, 2020 Processing time: 139 Days and 11.9 Hours
Core Tip
Core tip: Our study shows that there has been a change in the delta hepatitis virus-infected patient profile in our unit. Most patients infected in the 1980s, due to intravenous drug abuse, have progressed to cirrhosis and/or hepatocellular carcinoma and therefore still represent a significant burden on our Hepatology Unit. However, our main concern is with newly diagnosed patients, as there is a clear delay in the diagnosis of infection and cirrhosis. In addition, follow-up in their home countries has been poor. Most of them come from Eastern Europe and prior medical intervention was the main route of infection. We must also take into account the presence of comorbidities, e.g., metabolic syndrome and alcohol intake, which may contribute to the aggressive progression of the disease. Therefore, we must devote our efforts to controlling these aspects and finding an effective treatment, given the poor results offered by pegylated-α-interferon.
